|
|
|
|
|
|
|
Axsome Thera (AXSM)
|
|
3.45 -0.025 (-0.72%)
|
05-18 16:00
|
|
Open:
|
3.45
|
Pre. Close:
|
3.475
|
|
High:
|
3.4752
|
Low:
|
3.4
|
|
Volume:
|
75,467
|
Market Cap:
|
89M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
3.485 - 3.503
|
3.503 - 3.517
|
|
Low:
|
3.36 - 3.378
|
3.378 - 3.393
|
|
Close:
|
3.423 - 3.452
|
3.452 - 3.476
|
|
|
|
Technical analysis (as of: 2018-05-18 4:31:16 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 4.32 One year: 5.05
|
|
Support:
|
Support1: 2.93  Support2: 2.45
|
|
Resistance:
|
Resistance1:
3.70 Resistance2: 4.32
|
|
Pivot:
|
3.39
|
|
Moving Averages:
|
MA(5): 3.50 MA(20): 3.24
MA(100): 3.06 MA(250): 4.27
|
|
MACD:
|
MACD(12,26):
0.21 Signal(12,26,9): 0.21
|
|
%K %D:
|
%K(14,3): 70.69 %D(3): 77.89
|
|
RSI:
|
RSI(14): 66.99
|
|
52-Week:
|
High: 6.45
Low: 2.05 Change(%): -21.6
|
|
Average Vol(K):
|
3-Month: 19495
10-Days 13972
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.AXSM has closed below upper band by 34.8%. Bollinger Bands are 61.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to AXSM's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
|
|
|
Headline News
|
|
2018-05-14T12:27:31-04:00
Oryzon Genomics commences mid-stage study of Alzheimer's candidate
2018-05-08T12:34:10-04:00
Axsome Therapeutics' (AXSM) CEO Herriot Tabuteau on Q1 2018 Results - Earnings Call Transcript
2018-04-30T14:11:43-04:00
Week 18 Breakout Forecast: Short-Term Picks To Give You An Edge
2018-04-29T08:00:00-04:00
3 Things In Biotech, April 28: Fighting Mental Disorders, And A New Strategy For Bacteria?
2018-04-26T12:40:08-04:00
Midday Gainers / Losers (04/26/2018)
2018-04-26T09:23:53-04:00
Premarket Gainers as of 9:05 am (04/26/2018)
2018-04-26T08:34:35-04:00
Axsome's late-stage study of AXS-05 in treatment-resistant depression to continue; shares up 13% premarket
2018-04-24T08:00:00-04:00
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
